European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Investing.com -- The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

Ozempic and other GLP-1 drugs have forever altered the way people view, manage, and speak about obesity. However, it’s ...